Evidence map›Paper›PMID 40481959›Full record

ArticleNeurotoxicity research2025

Ketamine-Ethanol Combination Decreases Reduced Glutathione Levels and Activates both Intrinsic and Extrinsic Apoptotic Pathways Prior to Neuronal Death in SH-SY5Y Cells.

Felype Valentim Duarte Castelhano, Carolina Aparecida de Faria Almeida, Giulia de Assis Braz, Gabriela Otofuji Pereira, Rafaela Yolanda Silvino de Almeida, Matheus Lujan Pereira, Juliana Ligia Freires Ribeiro, Karin Argenti Simon, Rodrigo Portes Ureshino, Tania Marcourakis and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Neurotoxicity research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Felype Valentim Duarte Castelhano *Department of Pharmaceutical Sciences, Institute of Environmental, Chemical and Pharmaceutical Sciences, Universidade Federal de São Paulo, Rua São Nicolau, 210, 1° andar, Diadema, SP, 09913-030, Brazil.ORCID http://orcid.org/0009-0001-8641-8533
Carolina Aparecida de Faria Almeida *Department of Food and Drugs, School of Pharmaceutical Sciences, Federal University of Alfenas, Rua Gabriel Monteiro da Silva, 700, Alfenas, MG, 37130-001, Brazil.ORCID http://orcid.org/0000-0002-1231-2496
Giulia de Assis BrazDepartment of Pharmaceutical Sciences, Institute of Environmental, Chemical and Pharmaceutical Sciences, Universidade Federal de São Paulo, Rua São Nicolau, 210, 1° andar, Diadema, SP, 09913-030, Brazil.ORCID http://orcid.org/0009-0003-0150-2336
Gabriela Otofuji PereiraDepartment of Clinical and Toxicological Analysis, School of Pharmaceutical Sciences, University of São Paulo, Av. Prof. Lineu Prestes, 580, Bl. 13B, São Paulo, SP, 05508-000, Brazil.ORCID http://orcid.org/0009-0008-2648-3262
Rafaela Yolanda Silvino de AlmeidaDepartment of Pharmaceutical Sciences, Institute of Environmental, Chemical and Pharmaceutical Sciences, Universidade Federal de São Paulo, Rua São Nicolau, 210, 1° andar, Diadema, SP, 09913-030, Brazil.ORCID http://orcid.org/0009-0003-5415-6131
Matheus Lujan PereiraDepartment of Clinical and Toxicological Analysis, School of Pharmaceutical Sciences, University of São Paulo, Av. Prof. Lineu Prestes, 580, Bl. 13B, São Paulo, SP, 05508-000, Brazil.ORCID http://orcid.org/0009-0001-2352-1576
Juliana Ligia Freires RibeiroDepartment of Clinical and Toxicological Analysis, School of Pharmaceutical Sciences, University of São Paulo, Av. Prof. Lineu Prestes, 580, Bl. 13B, São Paulo, SP, 05508-000, Brazil.ORCID http://orcid.org/0009-0003-6920-0545
Karin Argenti SimonDepartment of Pharmaceutical Sciences, Institute of Environmental, Chemical and Pharmaceutical Sciences, Universidade Federal de São Paulo, Rua São Nicolau, 210, 1° andar, Diadema, SP, 09913-030, Brazil.ORCID http://orcid.org/0000-0002-4298-6176
Rodrigo Portes UreshinoDepartment of Biological Sciences, Universidade Federal de São Paulo, Diadema, SP, Brazil.ORCID http://orcid.org/0000-0003-3371-3376
Tania MarcourakisDepartment of Clinical and Toxicological Analysis, School of Pharmaceutical Sciences, University of São Paulo, Av. Prof. Lineu Prestes, 580, Bl. 13B, São Paulo, SP, 05508-000, Brazil.ORCID http://orcid.org/0000-0002-0076-5017
Larissa Helena TorresDepartment of Food and Drugs, School of Pharmaceutical Sciences, Federal University of Alfenas, Rua Gabriel Monteiro da Silva, 700, Alfenas, MG, 37130-001, Brazil.ORCID http://orcid.org/0000-0002-7065-7484
Raphael Caio Tamborelli GarciaDepartment of Pharmaceutical Sciences, Institute of Environmental, Chemical and Pharmaceutical Sciences, Universidade Federal de São Paulo, Rua São Nicolau, 210, 1° andar, Diadema, SP, 09913-030, Brazil. raphael.garcia@unifesp.br.ORCID http://orcid.org/0000-0002-7080-3955

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico undergraduate research scholarship (PIBIC)Fundação de Amparo à Pesquisa do Estado de São Paulo 2016/20796-2Fundação de Amparo à Pesquisa do Estado de São Paulo 2017/21834-8Fundação de Amparo à Pesquisa do Estado de São Paulo 2018/18582-0
6 · The paper itself

Abstract

Ketamine is an anesthetic drug that has been illegally used due to its hallucinogenic effects. Its use is often concomitant with drugs such as ethanol, which can cause irreversible damage to the central nervous system. This study investigates the neurotoxicity of ketamine-ethanol combination in human neuroblastoma SH-SY5Y cell line, exploring the mechanisms preceding cell death. Cell viability, oxidative stress parameters, and apoptosis pathways were assessed after 3 and 6 h of drug exposure. A concentration-response curve using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay determined the lowest observed adverse effect levels for ketamine (1 mM; K1) and ethanol (100 mM; E100). After 12, 24 and 48 h, MTT assay revealed a decrease in cell viability, with a possible synergistic effect in K1E100 at 48 h, confirmed by annexin-V/7-aminoactinomycin D flow cytometry analysis, which showed a higher proportion of late apoptotic cells. Mechanisms preceding cell death were assessed by measuring reduced glutathione (GSH) levels, glutathione-related enzymes activities, and apoptosis markers (caspase-8, Bax, Bcl-2, and caspase-3). GSH levels decreased after 6 h in E100 and K1E100. Glutathione peroxidase activity increased for all groups after 3 h and in K1 and K1E100 after 6 h. Glutathione reductase and glutathione S-transferase activities increased only for K1E100 after 3 h. K1E100 also showed increased caspase-8 and Bax expression after 3 and 6 h, respectively, indicating activation of both extrinsic and intrinsic apoptotic pathways. These results suggest that ketamine-ethanol combination induces neurotoxicity by triggering oxidative stress and apoptosis in a time-dependent manner prior to cell death, increasing the risk for neuronal damage compared to individual drug exposure. While these findings are promising, they should be interpreted with caution due to certain limitations, such as variability in enzyme activity measurements, reduced sample size for some markers, and the use of an immortalized, proliferative cell line. Further studies using differentiated neuronal cells are needed to validate and expand these observations.

Indexed as

ApoptosisEthanolGlutathioneKetamineNeuronsCell Line, TumorCell SurvivalDose-Response Relationship, DrugHumansNeuroblastomaOxidative StressEthanolGlutathioneKetamineApoptosisEthanolGlutathioneKetamineNeurotoxicity

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.